Urol. praxi, 2011; 12(6): 336-339

Metastatic renal cell carcinoma (mRCC), ten years of biological therapy: a help to patients or a waste of public health

MUDr.Michaela Matoušková, doc.MUDr.Miroslav Hanuš, CSc.
Urocentrum Praha

insurance resources?

Metastatic renal cell carcinoma is associated with a poor prognosis. The introduction of biological therapy only slowly changes the survival

and quality of life of patients. Tyrosine kinase inhibitors, mTOR inhibitors and anti-VEGF monoclonal antibodies are approved by

the regulatory bodies for the treatment of mRCC based on clinical trials. The therapeutic strategy is selected individually according to the

staging of the disease, the performance status and comorbidities of the patient, and the expected treatment toxicity. The identification

of prognostic factors for predicting survival allows to individualize therapeutic regimens.

Keywords: metastatic renal cell carcinoma, TKI inhibitors, mTOR inhibitors, anti-VEGF antibodies

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matoušková M, Hanuš M. Metastatic renal cell carcinoma (mRCC), ten years of biological therapy: a help to patients or a waste of public health. Urol. praxi. 2011;12(6):336-339.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530-2540. Go to original source... Go to PubMed...
    2. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011; 185(1): 60-66. Go to original source... Go to PubMed...
    3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27: 3312-3318. Go to original source... Go to PubMed...
    4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124. Go to original source... Go to PubMed...
    5. Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111. Go to original source... Go to PubMed...
    6. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068. Go to original source... Go to PubMed...
    7. Bex A, van der Veldt AAM, Blank C, et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. J Urol 2009; 27: 533-539. Go to original source... Go to PubMed...
    8. Abel EJ, Culp SH, Tannnir NM, et al. Primary tumor response to targeted agents in patients with metatatic renal cell carcinoma. Eur Urol 2011; 59: 10-15. Go to original source... Go to PubMed...
    9. Hora M, Stránský P, Eret V, et al. Integrace chirurgické a biologické léčby u pokročilého renálního karcinomu. Ces Urol 2010; 15(3): 149-157.
    10. Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281. Go to original source... Go to PubMed...
    11. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. Go to original source... Go to PubMed...
    12. Ljungberg B, Cowan NC, Hanbury DC, Hora M, et al. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Go to original source...
    13. Vyzula R, et al. Zásady cytostatické léčby. Update 7/2011

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.